Literature DB >> 16455912

Rapid susceptibility testing of medically important zygomycetes by XTT assay.

Charalampos Antachopoulos1, Joseph Meletiadis, Emmanuel Roilides, Tin Sein, Thomas J Walsh.   

Abstract

The XTT colorimetric assay quantifies fungal growth by measuring fungal metabolism and has been used successfully for susceptibility testing of Aspergillus species after 24 and 48 h of incubation. In the present study using 14 clinical isolates of Zygomycetes (Rhizopus oryzae [5 isolates], Cunninghamella spp. [3 isolates], Mucor spp. [3 isolates], and Absidia corymbifera [3 isolates]), significant metabolic activity was demonstrated before visual or spectrophotometric detection of fungal growth by performing the XTT assay as early as 6 h after inoculation. Testing of susceptibility to amphotericin B, posaconazole, and voriconazole was subsequently performed using the XTT method (100 microg/ml XTT, 25 microM menadione) at 6, 8, or 12 h after inoculation and the CLSI (formerly NCCLS) M38-A method with visual and spectrophotometric MIC determinations at 24 h after inoculation. Concentration-effect curves obtained with the use of the E(max) model (a sigmoid curve with variable slope) were comparable between the early XTT and spectrophotometric readings at 24 h. Complete inhibition of early metabolic activity with the azoles was delayed in comparison to that with amphotericin B. Using appropriate cutoff levels, agreement was demonstrated between the early XTT and 24-h spectrophotometric or visual readings. In particular, for MIC-0 (the lowest drug concentration showing absence of visual growth) of amphotericin B, overall agreement levels were 90 to 93% for the 6-h XTT assay and 100% for the 8- and 12-h time points. For MIC-0 of posaconazole, agreement levels were 86% for the 6-h XTT and 93 to 100% for the 8- and 12-h time points. The overall agreement levels for MIC-0 and MIC-2 (the lowest drug concentration showing prominent reduction of growth compared with the control well) of voriconazole (compared with 24-h spectrophotometric readings) were 93 to 98% for the 8- and 12-h XTT assays. These results support the use of the XTT method for rapid MIC determination for Zygomycetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455912      PMCID: PMC1392685          DOI: 10.1128/JCM.44.2.553-560.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

Review 2.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

3.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

Review 4.  Antifungal susceptibility testing. Current state of technology, limitations, and standardization.

Authors:  M A Pfaller; M G Rinaldi
Journal:  Infect Dis Clin North Am       Date:  1993-06       Impact factor: 5.982

5.  Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.

Authors:  Cristina Gil-Lamaignere; Regina Hess; Stefanie Salvenmoser; Kathrin Heyn; Reinhard Kappe; Frank-Michael C Müller
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

6.  Colorimetric assay for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 8.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

9.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

10.  Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay.

Authors:  S Arunmozhi Balajee; Alexander Imhof; Jennifer L Gribskov; Kieren A Marr
Journal:  J Antimicrob Chemother       Date:  2004-11-16       Impact factor: 5.790

View more
  12 in total

1.  Role of trehalose biosynthesis in Aspergillus fumigatus development, stress response, and virulence.

Authors:  Nadia Al-Bader; Ghyslaine Vanier; Hong Liu; Fabrice N Gravelat; Mirjam Urb; Christopher M-Q Hoareau; Paolo Campoli; Joseé Chabot; Scott G Filler; Donald C Sheppard
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

2.  CotH3 mediates fungal invasion of host cells during mucormycosis.

Authors:  Teclegiorgis Gebremariam; Mingfu Liu; Guanpingsheng Luo; Vincent Bruno; Quynh T Phan; Alan J Waring; John E Edwards; Scott G Filler; Michael R Yeaman; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

3.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.

Authors:  A Chakrabarti; M R Shivaprakash; I Curfs-Breuker; A Baghela; C H Klaassen; J F Meis
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

5.  Pseudomonas aeruginosa Inhibits the Growth of Scedosporium and Lomentospora In Vitro.

Authors:  Sharon C-A Chen; Shilpa Patel; Wieland Meyer; Belinda Chapman; Hong Yu; Karen Byth; Peter G Middleton; Helena Nevalainen; Tania C Sorrell
Journal:  Mycopathologia       Date:  2017-05-16       Impact factor: 2.574

6.  Mucormycosis in immunochallenged patients.

Authors:  Jane Pak; Veronica T Tucci; Albert L Vincent; Ramon L Sandin; John N Greene
Journal:  J Emerg Trauma Shock       Date:  2008-07

7.  Potential antifungal effects of human platelets against zygomycetes in vitro.

Authors:  Susanne Perkhofer; Barbara Kainzner; Beate E Kehrel; Manfred P Dierich; Walter Nussbaumer; Cornelia Lass-Flörl
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

Review 8.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

9.  Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes.

Authors:  Atef S Shehata; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  J Clin Microbiol       Date:  2008-10-01       Impact factor: 5.948

10.  Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of Scedosporium and Fusarium spp.

Authors:  Katerina Vikelouda; Maria Simitsopoulou; Lemonia Skoura; Charalampos Antachopoulos; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.